What This Document Is
This study guide is designed to help students prepare for the third exam (NR 293) in Chamberlain University’s Pharmacology I (NR 291) course. It focuses on key drug classes used in the treatment of hypertension, heart failure, angina, and related cardiovascular conditions. The guide summarizes essential information about mechanisms of action, indications, and adverse effects for a range of medications.
Why This Document Matters
This study guide is crucial for students needing a focused review of cardiovascular pharmacology before a major assessment. It’s most valuable when used *in conjunction with* course lectures, textbooks, and other learning materials. It exists to consolidate information and highlight important concepts for effective exam preparation. Students enrolled in NR 293 will find this guide particularly helpful in identifying areas needing further study.
Common Limitations or Challenges
This guide provides a condensed overview and does *not* replace the need for a comprehensive understanding of the underlying pharmacological principles. It is not a substitute for detailed textbook readings or clinical reasoning. The guide does not include practice questions or in-depth case studies. It’s a review tool, not a complete learning resource.
What This Document Provides
This study guide includes concise summaries of the following drug classes:
* Alpha2-adrenergic receptor stimulators (e.g., clonidine, methyldopa)
* Alpha1-blockers (e.g., doxazosin)
* Beta-blockers
* Angiotensin-converting enzyme (ACE) inhibitors (e.g., captopril, lisinopril)
* Angiotensin II receptor blockers (ARBs) (e.g., losartan)
* Calcium channel blockers (e.g., amlodipine, verapamil, diltiazem)
* Cardiac glycosides (e.g., digoxin)
* Antiarrhythmics (e.g., amiodarone)
It also briefly covers ischemic heart disease, myocardial infarction, and therapeutic objectives for angina.
This preview does NOT include
detailed explanations of nursing considerations, drug interactions beyond a single example, or comprehensive coverage of all possible adverse effects. It also does not include information on drug administration or monitoring parameters.
